Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | TSPO | P30536 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630072 | 0.89 | GRM5 (0.58) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| Basimglurant SCHEMBL29377966 | 0.85 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| Basimglurant SCHEMBL560590 | 0.85 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609263 | 0.83 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609433 | 0.81 | GRM5 (0.74) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608527 | 0.77 | GRM5 (0.83) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607411 | 0.76 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607722 | 0.76 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608562 | 0.74 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609394 | 0.74 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| CN-1960984-B | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | disclosed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| CN-1960984-A | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.